Tatiana V Abramihina

Learn More
Recent studies indicate that human pluripotent stem cell (PSC)-based therapies hold great promise in Parkinson's disease (PD). Clinical studies have shown that grafted fetal neural tissue can achieve considerable biochemical and clinical improvements in PD. However, the source of fetal tissue grafts is limited and ethically controversial. Human(More)
Human parthenogenetic stem cells are derived from the inner cell mass of blastocysts obtained from unfertilized oocytes that have been stimulated to develop without any participation of male gamete. As parthenogenesis does not involve the destruction of a viable human embryo, the derivation and use of human parthenogenetic stem cells does not raise the same(More)
New small molecules that regulate the step-wise differentiation of human pluripotent stem cells into dopaminergic neurons have been identified. The steroid, guggulsterone, was found to be the most effective inducer of neural stem cells into dopaminergic neurons. These neurons are extensively characterized and shown to be functional. We believe this new(More)
Cell therapy has attracted considerable interest as a promising therapeutic alternative for patients with Parkinson's disease (PD). Clinical studies have shown that grafted fetal neural tissue can achieve considerable biochemical and clinical improvements in PD. However, the source of fetal tissue grafts is limited and ethically controversial. Human(More)
Human pluripotent stem cells (PSC) have the potential to revolutionize regenerative medicine. However undifferentiated PSC can form tumors and strict quality control measures and safety studies must be conducted before clinical translation. Here we describe preclinical tumorigenicity and biodistribution safety studies that were required by the US Food and(More)
We studied neural induction and generation of neuroectoderm in the colonies of human parthenogenetic SC cultured in the presence of 5 and 19±2% oxygen. We found that neuroectoderm was more actively generated at high oxygen content. At the same time, the transcription of stem cell pluripotency genes was not completely suppressed during neural induction at(More)
We studied the effect of recombinant human activin A on induced neuroectoderm formation in colonies of human parthenogenetic SC in the absence of feeder cells. It was found that pretreatment of human parthenogenetic SC with activin A suppressed subsequent neural induction. Activin A in a concentration of 10 ng/ml significantly decreased transcriptional(More)
  • 1